Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Short reduced by 400k
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(328)
•••
Comment by Golddetectoron Sep 10, 2021 7:30am
172 Views
Post# 33838708

RE:RE:Short reduced by 400k

RE:RE:Short reduced by 400k

Kv I do not see much changed from milestones communicated earlier. Only thing late is the interim results of reborn that was expected in q3. It will be in q4 now. Redovu was always expected in q4. See below milestones. Most likely guy will plan the nr for q4 closely to drive the sp higher similar to what happened back in may imo. We shall see I guess. Gl longs.

Short-Term Value-Creating Milestones
QIXLEEF - PLENITUDE:
Q2: ACCELERATE PATIENT ENROLMENT
Q3: RECEIVE OPINION FROM EMA – MALTA COMPETENT AUTHORITY
QIXLEEF – REBORN1:
Q2: 1ST PATIENT IN
Q3: INTERIM ANALYSIS
Q3: RECEIVE OPINION FROM EMA – MALTA COMPETENT AUTHORITY Q1-22: END OF ENROLMENT
ARDS-003:
Q4: LAST HEALTHY VOLUNTEER Q1-22: LAST PATIENT IN
CAU M Z:
BRIDGE TO QIXLEEF
R ED U VO :
Q4:DIN EXPECTED
ENJOUCA :
MARKET LAUNCH DATES: CANADA Q4 2021, AUSTRALIA Q1 2022, GERMANY Q2 2022


and presentation link below. It shows also the financial planning for the rest of the year


https://s24.q4cdn.com/136309390/files/doc_presentation/2021/06/2021.05.28_Tetra-Bio-Pharma_AGM-Presentation_FINAL.pdf
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities